Evonile Pharma fixes ₹8.85 billion rights issue terms and record date
EVONILE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Rights Issue Committee fixed November 11, 2026 as the record date and approved 102,878,832 partly paid shares at ₹860 each, worth ₹8,847.54 million. The 5-for-12 entitlement opens November 19 and closes December 3. Investors pay ₹645 on application and ₹215 on the final call. Full subscription would raise total shares from 24,690,797 to 34,978,629.
Eligible holders need cash to maintain their stake; shareholders who do not subscribe will be diluted if the rights issue is fully subscribed.